- Home
- LSTA vs LGVN Comparison
LSTA vs LGVN Comparison
Compare LSTA & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSTA
- LGVN
- Stock Information
- Founded
- LSTA 1980
- LGVN 2014
- Country
- LSTA United States
- LGVN United States
- Employees
- LSTA N/A
- LGVN N/A
- Industry
- LSTA Misc Health and Biotechnology Services
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- LSTA Health Care
- LGVN Health Care
- Exchange
- LSTA Nasdaq
- LGVN Nasdaq
- Market Cap
- LSTA 20.9M
- LGVN 23.4M
- IPO Year
- LSTA N/A
- LGVN 2021
- Fundamental
- Price
- LSTA $2.94
- LGVN $1.30
- Analyst Decision
- LSTA Strong Buy
- LGVN Strong Buy
- Analyst Count
- LSTA 1
- LGVN 3
- Target Price
- LSTA $15.00
- LGVN $8.67
- AVG Volume (30 Days)
- LSTA 9.3K
- LGVN 138.8K
- Earning Date
- LSTA 08-11-2025
- LGVN 08-13-2025
- Dividend Yield
- LSTA N/A
- LGVN N/A
- EPS Growth
- LSTA N/A
- LGVN N/A
- EPS
- LSTA N/A
- LGVN N/A
- Revenue
- LSTA $1,000,000.00
- LGVN $2,225,000.00
- Revenue This Year
- LSTA N/A
- LGVN N/A
- Revenue Next Year
- LSTA N/A
- LGVN $51.48
- P/E Ratio
- LSTA N/A
- LGVN N/A
- Revenue Growth
- LSTA N/A
- LGVN 127.50
- 52 Week Low
- LSTA $1.87
- LGVN $1.14
- 52 Week High
- LSTA $4.20
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- LSTA 66.20
- LGVN 50.13
- Support Level
- LSTA $2.36
- LGVN $1.15
- Resistance Level
- LSTA $2.69
- LGVN $1.32
- Average True Range (ATR)
- LSTA 0.20
- LGVN 0.09
- MACD
- LSTA 0.01
- LGVN 0.01
- Stochastic Oscillator
- LSTA 90.77
- LGVN 45.31
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.